

# Annabelle A Okada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6630834/publications.pdf>

Version: 2024-02-01

23  
papers

1,145  
citations

516710

16  
h-index

677142

22  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1282  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup. <i>Advances in Therapy</i> , 2022, 39, 2984-2998.	2.9	3
2	Prognostic value of subfoveal choroidal thickness in new-onset acute Vogt-Koyanagi-Harada disease. <i>Clinical and Experimental Ophthalmology</i> , 2022, , .	2.6	0
3	Clinical features and visual outcomes of ocular sarcoidosis at a tertiary referral center in Tokyo. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, 260, 3357-3363.	1.9	4
4	Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet's disease. <i>British Journal of Ophthalmology</i> , 2021, 105, 1525-1533.	3.9	7
5	Pachychoroid: current concepts on clinical features and pathogenesis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 1385-1400.	1.9	40
6	Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 567-574.	1.9	14
7	Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. <i>Japanese Journal of Ophthalmology</i> , 2021, 65, 184-190.	1.9	52
8	Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2020, 4, 767-776.	2.4	30
9	Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR. <i>Advances in Therapy</i> , 2020, 37, 1173-1187.	2.9	144
10	Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1149-1156.	1.9	97
11	Epidemiology of Macular Edema in Uveitis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 169-180.	1.8	36
12	Association Study of ARMC9 Gene Variants with Vogt-Koyanagi-Harada Disease in Japanese Patients. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 699-705.	1.8	3
13	Serum levels of candidate microRNA diagnostic markers differ among the stages of non-small cell lung cancer. <i>Oncology Letters</i> , 2018, 16, 6643-6651.	1.8	26
14	Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 584-591.	1.9	16
15	One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2017, 237, 139-144.	1.9	24
16	Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 46-51.	1.8	33
17	Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 617-624.	5.2	106
18	One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy. <i>Ophthalmology</i> , 2015, 122, 1866-1872.	5.2	114

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Long-Term Efficacy and Safety of Infliximab Treatment for Uveitis in Behçet's Disease. <i>Ophthalmology</i> , 2014, 121, 1877-1884.	5.2	103
20	Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease. <i>JAMA Ophthalmology</i> , 2012, 130, 592.	2.4	149
21	Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. <i>British Journal of Ophthalmology</i> , 2011, 95, 1245-1250.	3.9	67
22	Cystoid Macular Edema in Uveitis. <i>Developments in Ophthalmology</i> , 2010, 47, 136-147.	0.1	37
23	Behçet's disease: general concepts and recent advances. <i>Current Opinion in Ophthalmology</i> , 2006, 17, 551-556.	2.9	40